Inogen, Inc (INGN) Q2 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

excellent job strengthening relationships with DMEs and winning tenders internationally. These results bolster our confidence in our total market approach and the strength of the image of brands. Turning to our second priority, driving profitability, where we continued to advance through operational excellence and disciplined cost management. In the second quarter, we delivered meaningful operating leverage, reducing operating expenses by approximately 5% year-over-year and generating $2.1 million in adjusted EBITDA. This is our second consecutive quarter of adjusted EBITDA profitability. It also marks the fourth adjusted EBITDA profitable quarter out of the last five, highlighting consistent execution of our strategies in disciplined expense management. As a result, we now expect to achieve full year adjusted EBITDA breakeven in 2025, supported by sustained revenue growth and disciplined spending. We remain focused on driving further improvement in the coming years as we advance towards sustainable profitability. We continued to advance our innovation pipeline this quarter with meaningful progress across our key strategic priorities. We introduced BOXY5, our latest stationary oxygen concentrator designed to expand access to high-quality therapy for long-term care patients. We also continued developments of clinical data for SIMIACs around the world and launched a new mobile digital health portal. I'll begin with VOXI5, our newest stationary oxygen concentrator. This product is a meaningful extension of our oxygen therapy portfolio, complementing our portable solutions and enabling us to serve a broader range of patients in a home care setting. Developed in collaboration with UL Medical, VOXI5 reflects the strength of a product pipeline in our ability to bring high-q...